Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at AACR Special Conference: Pancreatic CancerELI-002 2P induced T cell responses correlated wit...